Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density, published as a randomized controlled trial.

The women (n = 50-53/group) self-administered PTH (50, 75, or 100 microg) or placebo by daily sc injection for 12 months.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Parathyroid Hormone (PTH 1-84).

The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.

The methods mention a period of 12 months.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Biomarkers, Bone Density, Calcium, Femur Neck, Hip Joint and Lumbar Vertebrae.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in people with osteoporosis and bone density over 12 months.

The publication is from 2003 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.